Thermo Fisher Scientific Inc.
TMO Healthcare Medical - Diagnostics & Research NYSE
$572.77
$-2.47 (-0.43%)
Open: $578.00 | High: $579.09 | Low: $569.62 | Prev Close: $575.24
Market Cap: $217.08B
Volume: 980K | Avg: 2.1M
Last updated: December 05, 2025 at 10:06 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 490
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 33.11 |
| P/B Ratio | 4.24 |
| P/S Ratio | 4.96 |
| EPS | $17.30 |
| Beta | 0.91 |
| Shares Outstanding | 379.00M |
| 52-Week High | $610.97 |
| 52-Week Low | $385.46 |
| SMA 50 | $554.63 |
| SMA 200 | $480.83 |
| Dividend Yield | 0.29% |
| Annual Dividend | $1.68 |
| Next Earnings | January 29, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 39.8% |
| Operating Margin | 18.2% |
| Net Margin | 15.0% |
| ROE | 13.1% |
| ROA | 6.4% |
| Debt/Equity | 0.70 |
| Current Ratio | 1.50 |
| Quick Ratio | 1.11 |
Balance Sheet
| Total Assets | $97.32B |
| Total Liabilities | $47.65B |
| Total Equity | $49.58B |
| Cash | $4.01B |
| Total Debt | $32.77B |
| Net Debt | $28.76B |
Income Statement
| Revenue | $42.88B |
| Gross Profit | $17.73B |
| Operating Income | $7.66B |
| Net Income | $6.33B |
| EBITDA | $11.80B |
| Revenue/Share | $115.70 |
Cash Flow
| Operating CF | $8.67B |
| CapEx | $1.40B |
| Free Cash Flow | $7.27B |
| Book Value/Share | $134.98 |
| Tangible Book/Share | $-38.37 |
| Equity/Share | $134.98 |
Technical Indicators
| RSI (14) | 46.77 Neutral |
| MACD |
7.77
Signal: 10.40
|
| Volatility | 17.69% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +7.89% |
| Sharpe Ratio | 0.28 Fair |
| Volatility (Ann.) | 33.87% Moderate |
| TMO (1Y) | +7.89% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | -3.97% |
Sector Comparison (Healthcare)
| Metric | TMO | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 33.11 | 31.17 | 66% |
| P/B Ratio | 4.24 | -0.63 | 58% |
| ROE (%) | 13.11% | 9.75% | 47% |
| Net Margin (%) | 15.02% | 9.96% | 62% |
| Stock Score | 490 | 504.0 | 35% |
| 1Y Return (%) | +7.89% | +4.36% | 56% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TMO | $572.77 | $582.41 | $586.14 | $582.03 | $554.63 | $480.83 | 46.77 | 7.77 | 17.69% | 1961858 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the TMO stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| TMO | Market Today: WBD Sale Bids, Meta Cuts, Apple Shake-Up | Neutral | gurufocus.com | Read More |
| TMO | GENinCode surges on Thermo Fisher deal to roll out heart-disease test | Neutral | proactiveinvestors.co.uk | Read More |
| TMO | Market Today: Fed hopes lift stocks; AWS AI rollout; Prada-Versace deal | Neutral | gurufocus.com | Read More |
| TMO | TMO Stock Benefits From New Bioprocess Design Center in Asia | Neutral | zacks.com | Read More |
| TMO | First Look: Airbus trims targets, AWS AI, AEO hikes outlook | Neutral | gurufocus.com | Read More |
Company Information
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| CEO | Marc N. Casper |
| Employees | 125000 |
| Country | US |
| IPO Date | 1980-03-17 |
| Exchange | NYSE |
| Website | https://www.thermofisher.com |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
Similar Stocks (Healthcare - Medical - Diagnostics & Research)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category